AJP - Renal Information on EB 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Renal Physiol 286: F760-F766, 2004. First published November 25, 2003; doi:10.1152/ajprenal.00369.2003
0363-6127/04 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
286/4/F760    most recent
00369.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (16)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, D.
Right arrow Articles by Klein, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, D.
Right arrow Articles by Klein, J. D.

Role of vasopressin in diabetes mellitus-induced changes in medullary transport proteins involved in urine concentration in Brattleboro rats

Dongun Kim,1 Jeff M. Sands,1,2 and Janet D. Klein1

1Renal Division, Department of Medicine, and 2Department of Physiology, Emory University School of Medicine, Atlanta, Georgia 30322

Submitted 21 October 2003 ; accepted in final form 20 November 2003


   ABSTRACT
TOP
 ABSTRACT
METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
In rats with streptozotocin-induced diabetes mellitus for 10–20 days, we showed that the abundance of the major medullary transport proteins involved in the urinary concentrating mechanism, urea transporter (UT-A1), aquaporin-2 (AQP2), and the Na+-K+-2Cl- cotransporter (NKCC2/BSC1), is increased, despite the ongoing osmotic diuresis. To test whether vasopressin is necessary for these diabetes mellitus-induced changes in UT-A1, AQP2, or NKCC2/BSC1, we studied Brattleboro rats because they lack vasopressin. Brattleboro rats were given vasopressin (2.4 µg/day via osmotic minipump) for 5 or 12 days. At 5 days, vasopressin increased AQP2 protein abundance but decreased UT-A1 abundance compared with untreated Brattleboro rats. At 12 days, vasopressin increased the abundance of both UT-A1 and AQP2 proteins but did not alter NKCC2/BSC1. Next, untreated Brattleboro rats were made diabetic for 10 days by injecting them with streptozotocin (40 mg/kg). Diabetes mellitus increased the abundance of AQP2 and NKCC2/BSC1 proteins, but UT-A1 protein abundance did not increase. Third, vasopressin-treated Brattleboro rats were made diabetic with streptozotocin for 10 days. In vasopressin-treated Brattleboro rats, diabetes mellitus increased UT-A1, AQP2, and NKCC2/BSC1 protein abundances. Vasopressin significantly increased UT-A1 phosphorylation in vasopressin-treated diabetic Brattleboro rats but not in the other groups of Brattleboro rats. We conclude that 1) administering vasopressin to Brattleboro rats for 12 days, but not for 5 days, increases UT-A1 protein abundance and 2) vasopressin is necessary for the increase in UT-A1 protein in diabetic rats but is not necessary for the increase in AQP2 or NKCC2 proteins.

urea transporter; aquaporin; urinary concentrating ability; sodium/potassium/chloride cotransport

PATIENTS WITH UNCONTROLLED diabetes mellitus (type I) often have osmotic diuresis, due to unabsorbed glucose in the tubule lumen, and this can result in volume depletion. In rats, we showed that at 3–5 days of diabetes mellitus induced by streptozotocin (STZ), the urea transporter (UT-A1) protein abundance is decreased and aquaporin-2 (AQP2) protein abundance is unchanged in the inner medullary tip compared with control rats (10, 13). However, from 10–20 days, the abundance of the major medullary transport proteins involved in the urinary concentrating mechanism, UT-A1, AQP2, and the Na+-K+-2Cl- cotransporter (NKCC2/BSC1), is increased despite the ongoing osmotic diuresis (1, 10, 18, 26). Glucocorticoids mediate the early (3–5 days) decrease in UT-A1 protein abundance in rats with uncontrolled diabetes mellitus (13, 14, 17). However, the hormonal mediator of the subsequent increase in UT-A1, AQP2, and NKCC2/BSC1 is unknown.

One candidate mediator is vasopressin. Diabetic rats have elevated plasma vasopressin levels in some studies (4, 29) but not in another (10). However, measuring vasopressin levels in rats can be difficult because any factor that causes the rat to become anxious can result in a large and rapid release of vasopressin from the pituitary gland. The Brattleboro rat has central diabetes insipidus due to a congenital lack of vasopressin and is an excellent animal model for studying the effects of vasopressin (8). Previous studies of medullary transport proteins have generally administered vasopressin (or dDAVP, a V2-selective agonist) to Brattleboro rats for 5–7 days (5, 6, 11, 12, 27). Vasopressin increases AQP2 protein abundance in the inner medulla (5, 6, 12, 27). dDAVP increases NKCC2/BSC1 protein abundance in the outer medulla (11), although vasopressin does not (6). In contrast, vasopressin decreases UT-A1 protein abundance in the inner medulla (28). The goal of this study was to determine the effect of diabetes mellitus on UT-A1, AQP2, and NKCC2/BSC1 protein abundances in Brattleboro rats so that we could study the effect of diabetes in the absence of vasopressin.


   METHODS
TOP
 ABSTRACT
 METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Animal preparation. All animal protocols were approved by the Emory Institutional Animal Care and Use Committee. Male and female Brattleboro rats (bred in our animal facility) weighing 150–350 g received free access to 23% protein rat chow and water. To administer vasopressin, minipumps (Alzet model 2002, Durect, Cupertino, CA) delivering 2.4 µg/day of arginine vasopressin (Sigma, St. Louis, MO) were implanted subcutaneously under light ketamine anesthesia. Vasopressin was diluted with normal saline and infused at a rate of 12 µl/day for 12 days. A spot urine osmolality was measured every 2–3 days to confirm that the minipumps were working properly (model 5500 vapor pressure osmometer, Wescor, Logan, UT).

To induce diabetes mellitus, Brattleboro rats were injected with STZ (40 mg/kg body wt prepared fresh in 0.1 M citrate buffer, pH 4.0; Sigma) into a tail vein at 7 AM (10, 13, 21). Vasopressin-treated Brattleboro rats received STZ 2 days after the vasopressin-containing minipumps were placed. Diabetes mellitus was confirmed by measuring spot urine glucose at 24 and 48 h after STZ injection (Ames N-Multistix SG, Miles, Elkhart, IN).

Male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) weighing 125–200 g received free access to 23% protein rat chow and water for at least 3 days after delivery. To induce water diuresis, rats were given sugar water containing 10% glucose to drink for 14 days (24). The sugar water-fed rats do not develop glucosuria (24).

All rats were fed 23% protein chow and water (or sugar water) ad libitum throughout the study. Two days before death, rats were put into metabolic cages and 24-h urine was collected to measure urine volume, osmolality, and glucose and urea concentrations. Rats were killed by decapitation, and trunk blood was collected to measure glucose (One Touch Profile Diabetes Tracking Kit, Lifescan, Milpitas, CA), blood urea nitrogen (BUN; Infinity BUN reagent, Sigma), and osmolality.

Western blot analysis. Kidneys were removed and the medulla was dissected into outer medulla, inner medullary base, and inner medullary tip as previously described (10, 13). In some studies, one inner medulla was not subdivided, whereas the other kidney from the same rat was dissected into base and tip. Kidney tissue from a single rat was placed into ice-cold isolation buffer (10 mM triethanolamine, 250 mM sucrose, pH 7.6, 1 µg/ml leupeptin, and 2 mg/ml PMSF), homogenized, and SDS was added to a final concentration of 1% SDS for Western blot analysis of total cell lysate (10, 13). Total protein in each sample was measured by a modified Lowry method (Bio-Rad DC protein assay reagent, Bio-Rad, Richmond, CA). Proteins (10 µg/lane) were size separated by SDS-PAGE using 7.5, 10, or 15% polyacrylamide gels, blotted to polyvinylidene difluoride membranes (PVDF; Gelman Scientific, Ann Arbor, MI), and Western blotting was performed as described previously (10, 13). Western blots were probed with antibodies (diluted in TBS/Tween) to the following proteins: 1) UT-A1 (17), 2) AQP2 (10, 19), and 3) NKCC2/BSC1 (10, 11). Blots were quantified using an Imaging Densitometer GS670 and Molecular Analyst software (Bio-Rad). When reporting on total UT-A1 protein abundance differences, we make the assumption that the antibody recognizes both glycoproteins equally. The functional difference between these two glycoproteins, if any, is not known. In all cases, parallel gels were stained with Coomassie blue to confirm uniformity of loading (data not shown). Results are expressed as arbitrary units per microgram of protein.

Phosphorylation of UT-A1. Inner medullary collecting duct (IMCD) suspensions were incubated with 32P, and then UT-A1 protein was immunoprecipitated from equal amounts of the whole cell lysates as previously described (31). Proteins were size separated on two identical SDS-polyacrylamide gels containing an equal portion of the total immunoprecipitated protein per lane. The proteins on one gel were transferred to a PVDF membrane and the amount of immunoprecipitated UT-A1 was assayed by Western blotting. The other gel was dried, and 32P incorporation into UT-A1 was analyzed by autoradiography.

Statistics. Data are presented as means ± SE (n), where n indicates the number of rats studied. To test for statistically significant differences between two groups, a paired Student's t-test was used. To test for statistically significant differences between three or more groups, an ANOVA was used followed by a multiple comparison, protected t-test (25).


   RESULTS
TOP
 ABSTRACT
 METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Effect of administering vasopressin to Brattleboro rats on UT-A1, AQP2, and NKCC2/BSC1. Administering vasopressin to Brattleboro rats for 12 days significantly increased urine osmolality and reduced urine volume (Table 1). The protein abundances of both UT-A1 and AQP2 were significantly increased by 175 and 78%, respectively, in the inner medullary tip of 12-day vasopressin-treated Brattleboro rats compared with untreated Brattleboro rats (Figs. 1 and 2). However, there was no change in the protein abundance of NKCC2/BSC1 in the outer medulla (Fig. 3).


View this table:
[in this window]
[in a new window]
  		Table 1. Blood and urine parameters in Brattleboro rats

 


View larger version (36K):
[in this window]
[in a new window]
  		Fig. 1. Urea transporter (UT-A1) in inner medullary tip of untreated Brattleboro rats (BB CTR) and Brattleboro rats that received vasopressin (2.4 µg/day) for 12 days [BB VP (12d)]. A: Western blot of representative samples of inner medullary tip lysates probed with anti-UT-A1 antibody. B: densitometry of protein bands in arbitrary units. Rats receiving vasopressin had a 175% increase in UT-A1 protein abundance over levels in control rats. Values are means ± SE. *P < 0.05.

 


View larger version (31K):
[in this window]
[in a new window]
  		Fig. 2. Aquaporin-2 (AQP2) in inner medullary tip of BB CTR and BB VP (12d). A: Western blot of representative samples of inner medullary tip lysates probed with anti-AQP2 antibody. B: densitometry of protein bands in arbitrary units. Rats receiving vasopressin had a 78% increase in AQP2 protein abundance over levels in control rats. Values are means ± SE. *P < 0.05.

 


View larger version (26K):
[in this window]
[in a new window]
  		Fig. 3. Na+-K+-2Cl- cotransporter (NKCC2/BSC1) in outer medulla of BB CTR and Brattleboro rats that received vasopressin (2.4 µg/day) for 12 days (BB VP). A: Western blot of representative samples of outer medullary lysates probed with anti-NKCC2/BSC1 antibody. B: densitometry of protein bands in arbitrary units. There was no significant difference in the abundance of NKCC2/BSC1 in rats receiving vasopressin vs. control rats. Values are means ± SE.

 

Because the increase in UT-A1 at 12 days is opposite to previous results following 5 days of vasopressin (28), we performed two additional experiments. First, we measured UT-A1 abundance in the inner medullary tip and base from Brattleboro rats that received vasopressin for 5 days. We also measured it in whole inner medulla to provide a direct comparison to the previous study (28). UT-A1 protein abundance was decreased in the inner medullary tip and in whole inner medulla of 5-day vasopressin-treated Brattleboro rats, compared with untreated Brattleboro rats, consistent with the previous study (28), but did not change in the inner medullary base (Fig. 4). AQP2 protein abundance was increased in the inner medullary tip of the 5-day Brattleboro rats (Fig. 4), consistent with previous studies (5, 6, 12, 27). The Brattleboro rats treated with vasopressin for 5 days had comparable increases in urine osmolality and reductions in urine volume to rats treated for 12 days (data not shown).



View larger version (40K):
[in this window]
[in a new window]
  		Fig. 4. UT-A1 and AQP2 in inner medulla (IM) of BB CTR and Brattleboro rats that received vasopressin (2.4 µg/day) for 5 days [BB VP (5d)]. A–C: Western blots of representative tissue lysates: whole inner medulla (A), IM tip (B), and IM base (C); probed for UT-A1. D: Western blot of IM tip lysate probed for AQP2.

 

Second, we measured UT-A1, AQP2, and NKCC2/BSC1 protein abundances in Sprague-Dawley rats undergoing water diuresis for 14 days to reduce endogenous vasopressin levels. The water diuretic rats had significantly reduced urine osmolality and increased urine volume compared with control rats (Table 2). All three protein abundances were significantly decreased in the inner medullary tip (UT-A1, AQP2) or outer medulla (NKCC2/BSC1) of water diuretic rats compared with untreated Sprague-Dawley rats (Fig. 5).


View this table:
[in this window]
[in a new window]
  		Table 2. Blood and urine parameters in Sprague-Dawley rats

 


View larger version (34K):
[in this window]
[in a new window]
  		Fig. 5. UT-A1 and AQP2 in IM tip and NKCC2/BSC1 in the outer medulla (OM) of Sprague-Dawley control (SD Ctr) and water-diuretic rats (SD Hyd). Water-diuretic rats were given 10% sucrose in water for 14 days. Right: densitometic analyses of those results. UT-A1, AQP2, and NKCC2 protein abundances were significantly decreased in the water-diuretic rat, compared with control rats. Values are means ± SE. *P < 0.05.

 

Effect of diabetes mellitus on UT-A1, AQP2, and NKCC2/BSC1 in Brattleboro rats. Blood glucose was markedly increased in diabetic Brattleboro rats, both with and without vasopressin (Table 1). Neither vasopressin nor STZ changed BUN. Diabetic Brattleboro rats had significantly higher urine volume, urea excretion, and glucose excretion than control Brattleboro rats. Diabetes mellitus did not increase UT-A1 protein abundance in the inner medullary tip of Brattleboro rats (Fig. 6) but did increase AQP2 to 170% over control (Fig. 7). Diabetes mellitus also increased NKCC2/BSC1 protein abundance to 280% over control in the outer medulla (Fig. 8).



View larger version (44K):
[in this window]
[in a new window]
  		Fig. 6. UT-A1 in IM tip of control (BB CTR) and diabetic (BB DM) Brattleboro rats. A: Western blot of representative samples of IM tip lysates probed with anti-UT-A1 antibody. B: densitometry of protein bands in arbitrary units. There was no significant difference in the abundance of UT-A1 in diabetic Brattleboro rats compared with control Brattleboro rats. Values are means ± SE.

 


View larger version (29K):
[in this window]
[in a new window]
  		Fig. 7. AQP2 in IM tip of BB CTR and BB DM rats. A: Western blot of representative samples of IM tip lysates probed with anti-AQP2 antibody. B: densitometry of protein bands in arbitrary units. There was a 170% increase in the abundance of AQP2 in the diabetic brattleboro above control levels. Values are means ± SE. *P < 0.05.

 


View larger version (28K):
[in this window]
[in a new window]
  		Fig. 8. NKCC2/BSC1 in the OM of BB CTR and BB DM rats. A: Western blot of representative samples of OM lysates probed with anti-NKCC2/BSC1 antibody. B: densitometry of protein bands in arbitrary units. There was a 280% increase in the abundance of NKCC2/BSC1 in the diabetic Brattleboro rats above control levels. Values are means ± SE. *P < 0.05.

 

In Brattleboro rats that received vasopressin, diabetes mellitus again increased urine volume, urea excretion, and glucose excretion. In addition, diabetes mellitus decreased urine osmolality in vasopressin-treated Brattleboro rats compared with nondiabetic vasopressin-treated Brattleboro rats. In vasopressin-treated Brattleboro rats, diabetes mellitus increased the protein abundance of the 117-kDa UT-A1 glycoprotein to 69% over vasopressin alone but did not change the abundance of the 97-kDa UT-A1 glycoprotein (Fig. 9). UT-A1 typically runs as two glycoprotein bands (97 and 117 kDa) on Western blot (3). However, in Fig. 9, the 117-kDa band appears to have expanded to include some less glycosylated species between the 97- and 117-kDa bands. The Western blot was scanned as the discreet 97-kDa UT-A1 isoform, which did not change with diabetes (10), and the larger bands centering ~117 kDa were grouped for densitometic analysis. In Sprague-Dawley rats, it is the upper glycosylated species that are changed with diabetes (10). Diabetes mellitus also increased the protein abundances of AQP2 to 71% over vasopressin alone (Fig. 10) in the inner medullary tip and NKCC2/BSC1 to 37% over vasopressin alone in the outer medulla of vasopressin-treated Brattleboro rats (Fig. 11).



View larger version (50K):
[in this window]
[in a new window]
  		Fig. 9. UT-A1 in IM tip of vasopressin (VP) alone vs. VP and diabetes mellitus (VP + DM) in Brattleboro rats. A: Western blot of representative samples of IM tip lysates probed with anti-UT-A1 antibody. B: densitometry of the 117-kDa (filled bars) and 97-kDa (hatched bars) protein bands. The abundance of the 117-kDa UT-A1 glycoprotein was increased in VP + DM rats by 69% over VP alone. There was no statistical difference in the abundance of the 97-kDa glycoprotein isoform. Values are means ± SE. *P < 0.05. n.s., Not significant.

 


View larger version (23K):
[in this window]
[in a new window]
  		Fig. 10. AQP2 in IM tip of VP alone vs. VP + DM in Brattleboro rats. A: Western blot of representative samples of IM tip lysates probed with anti-AQP2 antibody. B: densitometry of protein bands. AQP2 protein abundance was increased in VP + DM rats by 71% over VP alone. Values are means ± SE. *P < 0.05.

 


View larger version (25K):
[in this window]
[in a new window]
  		Fig. 11. NKCC2/BSC1 in OM of VP alone vs. VP + DM in Brattleboro rats. A: Western blot of representative samples of OM lysates probed with anti-NKCC2/BSC1 antibody. B: densitometry of protein bands. NKCC2/BSC1 protein abundance was increased in VP + DM Brattleboro rats by 37% over VP alone. Values are means ± SE. *P < 0.05.

 

Phosphorylation of UT-A1 protein. The relative abundance of immunoprecipitated UT-A1 protein from IMCD suspensions was not different from the relative abundance of UT-A1 protein in whole cell lysate by Western blot analysis, i.e., control {approx} diabetes mellitus alone < vasopressin (12 days) alone < vasopressin and diabetes mellitus (Fig. 12). Only IMCD suspensions from the vasopressin-treated diabetic Brattleboro rats had a significant increase in UT-A1 phosphorylation to 190% over control Brattleboro rats. IMCD suspensions from the vasopressin-treated Brattleboro rats did not show any increase in UT-A1 phosphorylation despite a significant increase in UT-A1 protein abundance.



View larger version (33K):
[in this window]
[in a new window]
  		Fig. 12. Inner medullary collecting duct (IMCD) suspensions were metabolically labeled with 32P, and then UT-A1 protein was immunoprecipitated. A: Western blot of representative samples of IMCD suspensions from control (Ctrl), vasopressin-treated (VP), diabetes mellitus (DM), and vasopressin-treated diabetic (VP + DM) Brattleboro rats probed with anti-UT-A1 antibody. B: autoradiogram of phosphorylated UT-A1. Only IMCD suspensions from the VP-treated diabetic Brattleboro rats had a significant increase in UT-A1 phosphorylation to 190% over Ctrl Brattleboro rats.

 


   DISCUSSION
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The major findings in this study are that 1) administering vasopressin to Brattleboro rats for 12 days, but not for 5 days, increases UT-A1 protein abundance and 2) vasopressin is necessary for the increase in UT-A1 protein abundance in diabetic rats but is not necessary for the increase in AQP2 or NKCC2/BSC1 protein abundances. These findings suggest that the increase in the major medullary transport proteins involved in the urinary concentrating mechanism cannot be ascribed solely to vasopressin.

Effects of vasopressin in Brattleboro rats. Vasopressin gradually restores urinary concentrating ability in Brattleboro rats (8, 12). Correction of the urinary concentrating defect is associated with a progressive increase in inner medullary osmolality, primarily due to an increase in inner medullary urea content (8). After 3 days of vasopressin, inner medullary osmolality is only 50–75% of normal, but there is osmotic equilibration between urine and the inner medullary interstitium (8, 12). This finding suggests that the collecting duct is able to osmotically reabsorb water after 3 days of vasopressin, even though AQP2 protein abundance is subnormal (12). After 5 days of vasopressin, AQP2 protein abundance returns to normal levels (5, 6, 12, 27, and present study). After 14–28 days of vasopressin, urine and inner medullary osmolality are normal (8, 12), suggesting that urea content does not become normal until sometime between 3 and 14–28 days. After 5 days of vasopressin, UT-A1 protein abundance is decreased (28, present study) but is increased after 12 days (present study). This time course is consistent with Harrington and Valtin's and Kishore and colleagues' time courses (8, 12) and may help to explain the gradual correction of concentrating ability in Brattleboro rats.

Why the delayed increase in UT-A1 protein? The promoter for rat UT-A1 does not contain a consensus cAMP-response element (CRE) but does contain a tonicity enhancer element (15, 16). Thus it is possible that vasopressin may not directly increase UT-A1 transcription but may do so indirectly by increasing the transcription of other genes, such as AQP2, NKCC2/BSC1, that begin to increase inner medullary osmolality (9, 30). Consistent with this hypothesis is that UT-A1 protein abundance increases following 2 days of water diuresis (28) but decreases following 14 days of water diuresis (present study). Vasopressin does increase AQP2 transcription (30), which could account for the more rapid increase in AQP2 protein following vasopressin administration to Brattleboro rats.

The effect of vasopressin on NKCC2/BSC1 abundance has differed in different studies (2, 6, 11). Water restriction (which raises endogenous vasopressin levels) increases NKCC2/BSC1 protein abundance and a selective V2-receptor antagonist decreases it (2, 11), consistent with the presence of a CRE in the NKCC2/BSC1 promoter (9). In Brattleboro rats, dDAVP increases NKCC2/BSC1 abundance (11) but vasopressin does not (6). Knepper and colleagues (6) proposed that this difference may result from higher vasopressin levels following exogenous vasopressin administration resulting in V1a-receptor effects on the thick ascending limb that counteracts its V2-receptor effect to increase NKCC2/BSC1. The present study is consistent with this hypothesis, because exogenous vasopressin did not increase NKCC2/BSC1, but water diuresis (which reduces endogenous vasopressin levels) did decrease it. Other potential explanations for the difference between exogenous and endogenous vasopressin include a difference in sensitivity of the thick ascending limb vs. collecting duct to vasopressin (7) or the difference in half-life and duration of action of dDAVP vs. vasopressin (23).

Effect of diabetes mellitus in Brattleboro rats. Previous studies show that UT-A1, AQP2, and NKCC2/BSC1 protein abundances increase after 10 days of diabetes mellitus in Sprague-Dawley rats (1, 10, 18). In the present study, AQP2 and NKCC2/BSC1 protein abundances increased in diabetic Brattleboro rats, indicating that vasopressin is not required for the increase in these proteins in diabetes mellitus. AQP2 is known to be regulated by both vasopressin-dependent and -independent pathways (reviewed in Ref. 20). Promeneur and colleagues (22) showed that dehydration increases AQP2 protein in Brattleboro rats, even in the absence of vasopressin, and suggested that oxytocin is acting as an antidiuretic hormone through the V2 receptor. Thus it is possible that oxytocin is responsible for the increase in AQP2 protein in diabetic Brattleboro rats in the present study.

In contrast, UT-A1 protein abundance did not increase in diabetic Brattleboro rats but did increase in vasopressin-treated Brattleboro rats. This finding suggests that vasopressin is necessary for the increase in UT-A1 protein abundance during diabetes. It also suggests that a factor other than vasopressin is responsible for the increase in UT-A1 protein because vasopressin levels were not different between the two vasopressin-treated groups of Brattleboro rats. One potential mechanism for the upregulation of UT-A1 in the vasopressin-treated Brattleboro rats is an increase in luminal and/or interstitial osmolality or urea concentration, because diabetes does not change urine osmolality or urea concentration in untreated Brattleboro rats but does in the vasopressin-treated Brattleboro rats (Table 1).

Vasopressin also increased UT-A1 phosphorylation, but only in vasopressin-treated diabetic Brattleboro rats. We previously showed that an increase in UT-A1 phosphorylation by vasopressin correlates with an increase in vasopressin-stimulated urea transport in the rat IMCD (31). Thus, in the absence of vasopressin, diabetes mellitus does not increase UT-A1 protein abundance or its phosphorylation by vasopressin.

Summary. The abundances of the major medullary transport proteins involved in the urinary concentrating mechanism vary with time after the onset of diabetes mellitus in rats. At 3–5 days of diabetes mellitus, UT-A1 protein abundance is decreased in the inner medullary tip and AQP2 protein abundance is unchanged, compared with control rats, and this effect is mediated by glucocorticoids (10, 13). At 10–20 days of diabetes mellitus, UT-A1, AQP2, and NKCC2/BSC1 protein abundances are increased despite the ongoing osmotic diuresis (1, 10, 18, 26). The increases in AQP2 and NKCC2/BSC1 protein abundances are not mediated by vasopressin because these proteins increase in diabetic Brattleboro rats, but vasopressin is necessary for the increase in UT-A1 protein abundance.


   ACKNOWLEDGMENTS
 
Portions of this work have been published in abstract form (FASEB J 17: 333.10, 2003) and presented at the Experimental Biology 2003 meeting, April 11–15, 2003, San Diego, CA.

GRANTS

This work was supported by National Institutes of Health Grants R01-DK-41707 and R01-DK-63657.


   FOOTNOTES
 

Address for reprint requests and other correspondence: J. D. Klein, Emory Univ. School of Medicine, Renal Division, WMRB Rm. 338, 1639 Pierce Drive NE, Atlanta, GA 30322 (E-mail: jklei01{at}emory.edu).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Bardoux P, Ahloulay M, Le Maout S, Bankir L, and Trinh-Trang-Tan MM. Aquaporin-2 and urea transporter-A1 are upregulated in rats with type I diabetes mellitus. Diabetologia 44: 637-645, 2001.[CrossRef][Web of Science][Medline]
  2. Bertuccio CA, Ibarra FR, Toledo JE, Arrizurieta EE, and Martin RS. Endogenous vasopressin regulates Na-K-ATPase and Na+-K+-Cl- cotransporter rbsc-1 in rat outer medulla. Am J Physiol Renal Physiol 282: F265-F270, 2002.[Abstract/Free Full Text]
  3. Bradford AD, Terris J, Ecelbarger CA, Klein JD, Sands JM, Chou CL, and Knepper MA. 97- And 117-kDa forms of the collecting duct urea transporter UT-A1 are due to different states of glycosylation. Am J Physiol Renal Physiol 281: F133-F143, 2001.[Abstract/Free Full Text]
  4. Brooks DD, Nutting DF, Crofton JT, and Share L. Vasopressin in rats with genetic and streptozotocin-induced diabetes. Diabetes 38: 54-57, 1989.[Abstract]
  5. DiGiovanni SR, Nielsen S, Christensen EI, and Knepper MA. Regulation of collecting duct water channel expression by vasopressin in Brattleboro rat. Proc Natl Acad Sci USA 91: 8984-8988, 1994.[Abstract/Free Full Text]
  6. Ecelbarger CA, Terris J, Hoyer JR, Nielsen S, Wade JB, and Knepper MA. Localization and regulation of the rat renal Na+-K+-2Cl- cotransporter, BSC-1. Am J Physiol Renal Fluid Electrolyte Physiol 271: F619-F628, 1996.[Abstract/Free Full Text]
  7. Elalouf JM, Di Stefano A, and de Rouffignac C. Sensitivities of rat kidney thick ascending limbs and collecting ducts to vasopressin in vivo. Proc Natl Acad Sci USA 83: 2276-2280, 1986.[Abstract/Free Full Text]
  8. Harrington AR and Valtin H. Impaired urinary concentration after vasopressin and its gradual correction in hypothalamic diabetes insipidus. J Clin Invest 47: 502-510, 1968.[Web of Science][Medline]
  9. Igarashi P, Whyte DA, and Nagami GT. Cloning and kidney cell-specific activity of the promoter of the murine renal Na-K-Cl cotransporter gene. J Biol Chem 271: 9666-9674, 1996.[Abstract/Free Full Text]
  10. Kim DU, Sands JM, and Klein JD. Changes in renal medullary transport proteins during uncontrolled diabetes mellitus in rats. Am J Physiol Renal Physiol 285: F303-F309, 2003.[Abstract/Free Full Text]
  11. Kim GH, Ecelbarger CA, Mitchell C, Packer RK, Wade JB, and Knepper MA. Vasopressin increases Na-K-2Cl cotransporter expression in thick ascending limb of Henle's loop. Am J Physiol Renal Physiol 276: F96-F103, 1999.[Abstract/Free Full Text]
  12. Kishore BK, Terris JM, and Knepper MA. Quantitation of aquaporin-2 abundance in microdissected collecting ducts: axial distribution and control by AVP. Am J Physiol Renal Fluid Electrolyte Physiol 271: F62-F70, 1996.[Abstract/Free Full Text]
  13. Klein JD, Price SR, Bailey JL, Jacobs JD, and Sands JM. Glucocorticoids mediate a decrease in the AVP-regulated urea transporter in diabetic rat inner medulla. Am J Physiol Renal Physiol 273: F949-F953, 1997.[Abstract/Free Full Text]
  14. Mitch WE, Bailey JL, Wang X, Jurkovitz C, Newby DN, and Price SR. Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting. Am J Physiol Cell Physiol 276: C1132-C1138, 1999.[Abstract/Free Full Text]
  15. Nakayama Y, Naruse M, Karakashian A, Peng T, Sands JM, and Bagnasco SM. Cloning of the rat Slc14a2 gene and genomic organization of the UT-A urea transporter. Biochim Biophys Acta 1518: 19-26, 2001.[Medline]
  16. Nakayama Y, Peng T, Sands JM, and Bagnasco SM. The TonE/TonEBP pathway mediates tonicity-responsive regulation of UT-A urea transporter expression. J Biol Chem 275: 38275-38280, 2000.[Abstract/Free Full Text]
  17. Naruse M, Klein JD, Ashkar ZM, Jacobs JD, and Sands JM. Glucocorticoids downregulate the rat vasopressin-regulated urea transporter in rat terminal inner medullary collecting ducts. J Am Soc Nephrol 8: 517-523, 1997.[Abstract]
  18. Nejsum LN, Kwon TH, Marples D, Flyvbjerg A, Knepper MA, Frokiaer J, and Nielsen S. Compensatory increase in AQP2, p-AQP2, and AQP3 expression in rats with diabetes mellitus. Am J Physiol Renal Physiol 280: F715-F726, 2001.[Abstract/Free Full Text]
  19. Nielsen S, DiGiovanni SR, Christensen EI, Knepper MA, and Harris HW. Cellular and subcellular immunolocalization of vasopressin-regulated water channel in rat kidney. Proc Natl Acad Sci USA 90: 11663-11667, 1993.[Abstract/Free Full Text]
  20. Nielsen S, Frokiaer J, Marples D, Kwon ED, Agre P, and Knepper M. Aquaporins in the kidney: from molecules to medicine. Physiol Rev 82: 205-244, 2002.[Abstract/Free Full Text]
  21. Price SR, Bailey JL, Wang X, Jurkovitz C, England BK, Ding X, Phillips LS, and Mitch WE. Muscle wasting in insulinopenic rats results from activation of the ATP-dependent, ubiquitin-proteasome proteolytic pathway by a mechanism including gene transcription. J Clin Invest 98: 1703-1708, 1996.[Web of Science][Medline]
  22. Promeneur D, Kwon TH, Frokiaer J, Knepper MA, and Nielsen S. Vasopressin V2-receptor-dependent regulation of AQP2 expression in Brattleboro rats. Am J Physiol Renal Physiol 279: F370-F382, 2000.[Abstract/Free Full Text]
  23. Richardson DW and Robinson AG. Desmopressin. Ann Intern Med 103: 228-239, 1985.[CrossRef][Web of Science][Medline]
  24. Sands JM and Schrader DC. Coordinated response of renal medullary enzymes regulating net sorbitol production in diuresis and antidiuresis. J Am Soc Nephrol 1: 58-65, 1990.[Web of Science][Medline]
  25. Snedecor GW and Cochran WG. Statistical Methods. Ames, IA: Iowa State Univ. Press, 1980.
  26. Song J, Knepper MA, Verbalis JG, and Ecelbarger CA. Increased renal ENaC subunit and sodium transporter abundances in streptozotocin-induced type 1 diabetes. Am J Physiol Renal Physiol 285: F1125-F1137, 2003.[Abstract/Free Full Text]
  27. Terris J, Ecelbarger CA, Nielsen S, and Knepper MA. Long-term regulation of four renal aquaporins in rats. Am J Physiol Renal Fluid Electrolyte Physiol 271: F414-F422, 1996.[Abstract/Free Full Text]
  28. Terris J, Ecelbarger CA, Sands JM, and Knepper MA. Long-term regulation of collecting duct urea transporter proteins in rat. J Am Soc Nephrol 9: 729-736, 1998.[Abstract]
  29. Trinder D, Phillips PA, Stephenson JM, Risvanis J, Aminian A, Adam W, Cooper M, and Johnston CI. Vasopressin V1 and V2 receptors in diabetes mellitus. Am J Physiol Endocrinol Metab 266: E217-E223, 1994.[Abstract/Free Full Text]
  30. Yasui M, Zelenin SM, Celsi G, and Aperia A. Adenylate cyclase-coupled vasopressin receptor activates AQP2 promoter via a dual effect on CRE and AP1 elements. Am J Physiol Renal Physiol 272: F443-F450, 1997.[Abstract/Free Full Text]
  31. Zhang C, Sands JM, and Klein JD. Vasopressin rapidly increases the phosphorylation of the UT-A1 urea transporter activity in rat IMCDs through PKA. Am J Physiol Renal Physiol 282: F85-F90, 2002.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 PhysiologyHome page
M. S. Kwon, S. W. Lim, and H. M. Kwon
Hypertonic Stress in the Kidney: A Necessary Evil
Physiology, June 1, 2009; 24(3): 186 - 191.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
Y.-M. Kim, W.-Y. Kim, H.-W. Lee, J. Kim, H. M. Kwon, J. D. Klein, J. M. Sands, and D. Kim
Urea and NaCl regulate UT-A1 urea transporter in opposing directions via TonEBP pathway during osmotic diuresis
Am J Physiol Renal Physiol, January 1, 2009; 296(1): F67 - F77.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
M. A. Blount, J. M. Sands, K. J. Kent, T. D. Smith, S. R. Price, and J. D. Klein
Candesartan augments compensatory changes in medullary transport proteins in the diabetic rat kidney
Am J Physiol Renal Physiol, June 1, 2008; 294(6): F1448 - F1452.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
S. Tiwari, S. Riazi, and C. A. Ecelbarger
Insulin's impact on renal sodium transport and blood pressure in health, obesity, and diabetes
Am J Physiol Renal Physiol, October 1, 2007; 293(4): F974 - F984.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
J. D. Klein, B. P. Murrell, S. Tucker, Y.-H. Kim, and J. M. Sands
Urea transporter UT-A1 and aquaporin-2 proteins decrease in response to angiotensin II or norepinephrine-induced acute hypertension
Am J Physiol Renal Physiol, November 1, 2006; 291(5): F952 - F959.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. D. Klein, O. Frohlich, M. A. Blount, C. F. Martin, T. D. Smith, and J. M. Sands
Vasopressin Increases Plasma Membrane Accumulation of Urea Transporter UT-A1 in Rat Inner Medullary Collecting Ducts
J. Am. Soc. Nephrol., October 1, 2006; 17(10): 2680 - 2686.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
Q. Cai, M. Keck, M. R. McReynolds, J. D. Klein, K. Greer, K. Sharma, J. B. Hoying, J. M. Sands, and H. L. Brooks
Effects of water restriction on gene expression in mouse renal medulla: identification of 3betaHSD4 as a collecting duct protein
Am J Physiol Renal Physiol, July 1, 2006; 291(1): F218 - F224.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
C. Li, W. Wang, S. N. Summer, M. A. Cadnapaphornchai, S. Falk, F. Umenishi, and R. W. Schrier
Hyperosmolality In Vivo Upregulates Aquaporin 2 Water Channel and Na-K-2Cl Co-Transporter in Brattleboro Rats
J. Am. Soc. Nephrol., June 1, 2006; 17(6): 1657 - 1664.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
S.-W. Lim, K.-H. Han, J.-Y. Jung, W.-Y. Kim, C.-W. Yang, J. M. Sands, M. A. Knepper, K. M. Madsen, and J. Kim
Ultrastructural localization of UT-A and UT-B in rat kidneys with different hydration status
Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2006; 290(2): R479 - R492.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
D. Kim, J. D. Klein, S. Racine, B. P. Murrell, and J. M. Sands
Urea may regulate urea transporter protein abundance during osmotic diuresis
Am J Physiol Renal Physiol, January 1, 2005; 288(1): F188 - F197.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
C. Li, J. D. Klein, W. Wang, M. A. Knepper, S. Nielsen, J. M. Sands, and J. Frokiaer
Altered expression of urea transporters in response to ureteral obstruction
Am J Physiol Renal Physiol, June 1, 2004; 286(6): F1154 - F1162.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
286/4/F760    most recent
00369.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (16)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, D.
Right arrow Articles by Klein, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, D.
Right arrow Articles by Klein, J. D.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.